CC Class Action Notice: Chemours Sued for Securities Fraud After Opteon Demand Issues Lead to 18% Stock Drop — Investors Urged to Contact BFA Law by December 7 Deadline
For best results when printing this announcement, please click on link below: CC Class Action Notice: Chemours Sued for Securities Fraud After Opteon Demand Issues Lead to 18% Stock Drop — Investors Urged to Contact BFA Law by December 7 Deadline Chemours has been sued for securities fraud after its stock plummeted 18.63% because Chemours allegedly misrepresented the strength of demand for its Opteon products. Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against The Chemours Company (NYSE:CC) and certain of the company’s senior executives for securities fraud after a significant stock drop resulting from potential violations of the federal securities laws. If you invested in Chemours, you are encouraged to obtain additional information by visiting: Key Details of the Chemours ($CC) Class Action: Lead Plaintiff Deadline: December 7, 2026 Alleged Misconduct: Securities fraud alleging Chemours misrepresented the strength of demand for its Opteon products Stock Drop: August 5, 2026 — 18.63% Stock Drop Court: U.S. District Court for the District of Delaware Action: Contact BFA Law to discuss your rights Investors
63% because Chemours allegedly misrepresented the strength of demand for its Opteon products. Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against The Chemours Company (NYSE:CC) and certain of the company’s senior executives for securities fraud after a significant stock drop resulting from potential violations of the federal securities laws. S. District Court for the District of Delaware Action: Contact BFA Law to discuss your rights Investors have until December 7, 2026 to ask the Court to be appointed to lead the case.
The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Chemours securities. S. District Court for the District of Delaware. It is captioned Darcy v.
The Chemours Company, No. 26-cv-1299. Why is Chemours Being Sued for Securities Fraud? Chemours offers a range of industrial and specialty chemical products, including Opteon, a set of refrigeration chemicals with a reduced ozone-depletion footprint.
S. AIM Act, which directed the EPA to oversee the transition to alternative refrigerants that present a lesser impact to the ozone layer. According to the complaint, Chemours stated that continued adoption of the AIM Act drove sustained growth for its Opteon products. Chemours stated that the “sustained double-digit” Opteon expansion would be “driven by the continued regulatory adoption” of the AIM Act.
What’s more, Chemours provided 2026 net sales guidance of 3% to 5% growth and 2026 adjusted EBITDA guidance of $800M — $900M, driven by “higher... demand” in its Opteon segment. ” Why did Chemours’s Stock Drop? On August 4, 2026, Chemours announced Q2 2026 financial results, revealing an approximately 1% year-over-year decrease in net sales and cutting 2026 adjusted EBITDA guidance by about 11% (to $775M — $825M from $800M — $900M).
59 per share on August 5, 2026. Click here for more information: What Can You Do? If you invested in Chemours, you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis; there is no cost to you.
Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. 3619 Why Bleichmar Fonti & Auld LLP? BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation.
It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360, and “SuperLawyers” by Thomson Reuters. ’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd. For more information about BFA and its attorneys, please visit ( ) Attorney advertising.
Past results do not guarantee future outcomes. 3619